A recent breakthrough impacts cancer research: IRCM researchers uncover a key<br>mechanism in the control of cell motility

MONTREAL, Oct. 28 /CNW Telbec/ - A team of scientists at the Institut de recherches cliniques de Montréal (IRCM) led by Dr. Jean-François Côté, Director of the Cytoskeletal Organization and Cell Migration research unit, identified a novel molecular mechanism in the control of cell motility. Their findings were published online today in Current Biology, a journal from the Cell Press group. This scientific breakthrough could eventually lead to the development of new cancer-treating drugs that could block the spread of tumours (metastasis).

"As many as 90% of cancer patient deaths are attributable to metastasis, which explains the importance of understanding the molecular mechanisms at the basis of this harmful process," says Dr. Côté. "This is why, over the past few years, we have focused our research on DOCK180, a protein involved in intracellular signalling networks, and more particularly on the DOCK180/Rac1 signalling pathway, which is suspected to be a key mediator of tumour metastasis."

Unlike normal cells that migrate throughout embryonic and adult life to perform their specialized functions, cancer cells metastasize in order to lethally spread throughout the body. At a molecular level, DOCK180 specifically activates the small Rac1 protein, which, in turn, modifies a cell's shape and promotes cell motility and invasion. Dr. Côté's team had previously demonstrated in detail how DOCK180, with the help of its binding partner ELMO, acts on Rac1 to promote robust cell migration.

"We knew that this signalling pathway had to be regulated to prevent uncontrolled cell migration in normal conditions, but until now, the mechanisms involved had been eluding us and other scientists," explains Manishha Patel, a PhD student in Dr. Côté's laboratory and co-author of the study. "With our recent findings, we demonstrated that the ELMO protein closes in on itself to enter a repressed state, thus preventing the activation of the DOCK180/Rac pathway."

"Our team identified three regions in ELMO that allow it to toggle between a closed/inactive and open/active shape," adds Dr. Yoran Margaron, a postdoctoral fellow in the same research unit and one of the article's co-authors. "We showed that if we disrupt ELMO's regulatory feature and maintain the protein in an open state, we can fully activate the DOCK180/Rac pathway and significantly increase the migration potential of cells."

The researchers' next step is to investigate the regulation of ELMO in cancer cells. Based on their latest findings, they will attempt to maintain ELMO in a repressed state within cancer cells to prevent metastasis, which could have a major impact on the development of potential cancer treatments.

This research project was supported by the Canadian Institutes of Health Research (CIHR) and the Canadian Foundation for Innovation (CFI). Other collaborators for this study include Nadine Fradet, Qi Yang and Brian Wilkes from the IRCM, as well as Dr. Michel Bouvier from the Institut de recherche en immunologie et en cancérologie (IRIC), and Dr. Kay Hoffman from Miltenyi Biotec in Germany.

For more information, please refer to the online article published by Current Biology: http://www.cell.com/current-biology/newarticles. The print publication will be available on November 23, 2010.

About Dr. Jean-François Côté

Jean-François Côté obtained his PhD in biochemistry from McGill University. He is Director of the Cytoskeletal Organization and Cell Migration research unit at the IRCM. Dr. Côté is Associate IRCM Research Professor, and Associate researcher in the Department of Medicine at the Université de Montréal, with an accreditation in molecular biology. He is also an Associate member of the Department of Medicine at McGill University. Dr. Côté holds a new investigator award from the Canadian Institutes of Health Research (CIHR).

About the Institut de recherches cliniques de Montréal (IRCM)

Founded in 1967, the IRCM (www.ircm.qc.ca) is currently comprised of 37 research units in various fields, namely immunity and viral infections, cardiovascular and metabolic diseases, cancer, neurobiology and development, and systems biology and medicinal chemistry. It also houses three specialized research clinics, as well as eight core facilities and two research platforms with state-of-the-art equipment. The IRCM employs 450 people and is an independent institution affiliated with the Université de Montréal. The IRCM clinic is associated to the Centre hospitalier de l'Université de Montréal (CHUM). The IRCM also maintains a long-standing association with McGill University.

For further information:

For more information and to schedule an interview with Dr. Côté, please contact: